You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
Antibodies to the A27 Protein of Vaccinia Virus Neutralize and Protect against Infection but Represent a Minor Component of Dryvax Vaccine-Induced Immunity
Yong He, Jody Manischewitz, Clement A. Meseda, Michael Merchlinsky, Russell A. Vassell, Lev Sirota, Ira Berkower, Hana Golding and Carol D. Weiss
The Journal of Infectious Diseases
Vol. 196, No. 7 (Oct. 1, 2007), pp. 1026-1032
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30087429
Page Count: 7
Preview not available
The smallpox vaccine Dryvax, which consists of replication-competent vaccinia virus, elicits antibodies that play a major role in protection. Several vaccinia proteins generate neutralizing antibodies, but their importance for protection is unknown. We investigated the potency of antibodies to the A27 protein of the mature virion in neutralization and protection experiments and the contributions of A27 antibodies to Dryvax-induced immunity. Using a recombinant A27 protein (rA27), we confirmed that A27 contains neutralizing determinants and that vaccinia immune globulin (VIG) derived from Dryvax recipients contains reactivity to A27. However, VIG neutralization was not significantly reduced when A27 antibodies were removed, and antibodies elicited by an rA27 enhanced the protection conferred by VIG in passive transfer experiments. These findings demonstrate that A27 antibodies do not represent the major fraction of neutralizing activity in VIG and suggest that immunity may be augmented by vaccines and immune globulins that include strong antibody responses to A27.
The Journal of Infectious Diseases © 2007 Oxford University Press